Filing Flows › Comparisons › SER vs COCP
Serina Therapeutics vs Cocrystal Pharma: SER and COCP compared
Serina Therapeutics is the larger company: $130K of revenue in its latest quarter (Q2 2025) against $105K for Cocrystal Pharma (Q2 2026).
Where the money goes: SER and COCP
Serina Therapeutics (SER) · Q2 2025
Serina Therapeutics, Q2 2025: revenue $130K (+155% year over year), net loss $6.5M, operating cash flow −$3.8M. The chart follows the revenue to costs, profit and cash.
Cocrystal Pharma (COCP) · Q2 2026
Cocrystal Pharma, Q2 2026: revenue $105K, net loss $3.2M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
| Serina Therapeutics (SER) | Cocrystal Pharma (COCP) | |
|---|---|---|
| Latest quarter | Q2 2025 | Q2 2026 |
| Revenue | $130K | $105K |
| Revenue growth, Y/Y | +155% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$6.5M | −$3.2M |
| Operating cash flow | −$3.8M | −$2.5M |
Questions
Which is bigger, Serina Therapeutics or Cocrystal Pharma?
Serina Therapeutics is the larger company: $130K of revenue in its latest quarter (Q2 2025) against $105K for Cocrystal Pharma (Q2 2026).
More: Serina Therapeutics earnings · how Serina Therapeutics makes money · Cocrystal Pharma earnings · how Cocrystal Pharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2025; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.